HEALTHCARE UTILIZATION AND COSTS IN PULMONARY ARTERIAL HYPERTENSION (PAH) PATIENTS TREATED WITH ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) OR PHOSPHODIESTERASE TYPE 5 INHIBITORS (PDE5IS)

被引：0
|
作者：
Hill, J. [1 ]
Lickert, C. [2 ]
Cole, M. [2 ]
McGuiness, K. [1 ]
Wade, R. L. [1 ]
Drake, W. [2 ]
机构：
[1] QuintielsIMS, Plymouth Meeting, PA USA
[2] Actelion Pharmaceut Inc, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV10
引用
下载
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [41] Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis
    Lopamudra Kirtania
    Rituparna Maiti
    Anand Srinivasan
    Archana Mishra
    Clinical Drug Investigation, 2019, 39 : 1031 - 1044
  • [42] Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease
    Clave, Mariana M.
    Maeda, Nair Y.
    Thomaz, Ana M.
    Bydlowski, Sergio P.
    Lopes, Antonio A.
    CONGENITAL HEART DISEASE, 2019, 14 (02) : 246 - 255
  • [43] Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials
    Karedath, Jithin
    Dar, Hassaan
    Ganipineni, Vijay Durga Pradeep
    Gorle, Sri Anjali
    Gaddipati, Sarvani
    Bseiso, Anan
    Pizzorno, Guiomarly
    Shaik, Tanveer Ahamad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [44] Target Distribution of PDE-5 Inhibitors and Endothelin-1 Receptor Antagonists - an immunohistological Study on Human in vivo derived Pulmonary Vessels
    Hertling, Stefan Ferdinand
    von Schwendi, Marietta Suesskind
    INTERNIST, 2018, 59 : S10 - S10
  • [45] CLINICAL IMPROVEMENT IN PATIENTS WITH EXERCISE INDUCED PULMONARY ARTERY HYPERTENSION AFTER 6 MONTHS OF PHOSPHODIESTERASE-5 INHIBITORS OR ENDOTHELIAL RECEPTOR ANTAGONISTS OR BOTH
    Mannem, Santhosh R.
    Salamon, Jason
    Gunda, Sampath
    Iqbal, Muhammed
    Bhandari, Manoj
    Mazurek, Jeremy
    Zolty, Ronald
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A1660 - A1660
  • [46] SWITCHING TO RIOCIGUAT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION NOT AT TREATMENT GOAL WITH PHOSPHODIESTERASE TYPE-5 INHIBITORS: SUBGROUP ANALYSIS RESULTS OF THE REPLACE STUDY
    Hoeper, Marius
    Ghofrani, Hossein
    Al-Hiti, Hikmet
    Benza, Raymond
    Chang, Sung A.
    Corris, Paul
    Simon, J.
    Ekkehard, Gibbs
    Pavel, Grunig
    James, Jansa
    David, Klinger
    Vallerie, Langleben
    Gisela, McLaughlin
    Jaquelina, Meyer
    Andrew, Ota-Arakaki
    Tomas, Peacock
    Stephan, Pulido
    Carmine, Rosenkranz
    Vizza, Dario
    Vonk, Anton
    White, Noordegraaf R.
    Chang, Mikyung
    Kleinjung, Frank
    Meier, Christian
    Paraschin, Karen
    Simonneau, Gerald
    CHEST, 2020, 158 (04) : 2156A - 2159A
  • [47] Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study) A Randomized Controlled Trial
    Tapson, Victor E.
    Torres, Fernando
    Kermeen, Fiona
    Keogh, Anne M.
    Allen, Roblee P.
    Frantz, Robert P.
    Badesch, David B.
    Frost, Adaani E.
    Shapiro, Shelley M.
    Laliberte, Kevin
    Sigman, Jeffrey
    Arneson, Carl
    Galie, Nazzareno
    CHEST, 2012, 142 (06) : 1383 - 1390
  • [48] Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-aIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence
    Nardone, Beatrice
    Orrell, Kelsey A.
    Vakharia, Paras P.
    West, Dennis P.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (02) : 139 - 147
  • [49] The Benefits of the Use of Chronic Phosphodiesterase 5 Inhibitors (PDE5) in Patients with Heart Failure with Reduced Ejection Fraction and Secondary Pulmonary Hypertension: a Single Center Study
    Al Qaseer, M.
    Raleigh, C.
    Egan, S.
    McAdam, Brendan
    IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : S394 - S394
  • [50] Can Combination Therapy with Endothelin Receptor Antagonist and PDE5 Inhibitors Prevent Echocardiographic Findings Suspicious for Pulmonary Arterial Hypertension? Description of a Real-Life Case Series
    Damiani, Arianna
    Lepri, Gemma
    Bonomi, Francesco
    Fiorentini, Elisa
    Peretti, Silvia
    Blagojevic, Jelena
    Randone, Silvia Bellando
    Guiducci, Serena
    DIAGNOSTICS, 2024, 14 (14)
12345